Table 1.
States Reporting Widespread Implementation§ of EBPs: 2007–2009
| Evidence-Based Practices | 2007 (N = 50) | 2008 (N = 51) | 2009 (N = 51) | |||
|---|---|---|---|---|---|---|
| M (SD) | N (%) | M (SD) | N (%) | M (SD) | N (%) | |
| Screening and brief intervention | 2.48 (.97) | 7 (13.7) | 2.32 (.94) | 6 (11.8) | 2.41 (.92) | 6 (11.8) |
| Overall psychosocial interventions | 3.24 (.82) | 16 (31.4) | 3.84 (.82) | 35 (68.6) | 3.66 (.77) | 32 (62.7)*,‡ |
| Individual psychosocial interventions | ||||||
| ASAM Placement Criteria | 39 (76.5) | 39 (76.5) | ||||
| MI/MET | 30 (58.8) | 40 (78.4)† | ||||
| CBT | 28 (54.9) | 36 (70.6) | ||||
| Matrix model | 8 (15.7) | 11 (21.6) | ||||
| Seeking Safety | 9 (17.6) | 10 (19.6) | ||||
| DBT | 7 (13.7) | 9 (17.6) | ||||
| Overall medication-assisted treatment | 2.62 (.99) | 8 (15.7) | 3.14 (1.01) | 18 (35.3) | 2.96 (.92) | 15 (29.4)*,‡ |
| Individual medication-assisted treatment | ||||||
| Methadone | 36 (70.6) | 34 (66.7) | ||||
| Buprenorphine | 11 (21.6) | 7 (13.7) | ||||
| Oral naltrexone | 3 (5.9) | 6 (11.8) | ||||
| Disulfiram | 5 (9.8) | 6 (11.8) | ||||
| Injectable naltrexone | 2 (3.9) | |||||
| Smoking cessation | 18 (35.3) | |||||
*
Significant (p < .05) increase from 2007 to 2008.
†
Significant (p < .05) increase from 2008 to 2009.
‡
Significant (p < .05) increase from 2007 to 2009.
§
Widespread implementation defined as 4 = considerably implemented or 5 = extensively implemented on the 5-point Likert-type scale vs. 1 = not at all implemented, 2 = slightly implemented, or 3 = moderately implemented.
Psychosocial interventions: ASAM = American Society of Addiction Medicine—Patient Placement Criteria; MI/MET = motivational interviewing/motivational enhancement therapy; CBT = cognitive behavioral therapy; DBT = dialectical behavior therapy.